Research programme: glaucoma therapeutics - Icagen
Latest Information Update: 24 Jul 2007
At a glance
- Originator Icagen
- Mechanism of Action Ion channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 24 Jul 2007 Discontinued - Preclinical for Glaucoma in USA (Ophthalmic)
- 21 Aug 2006 Preclinical trials in Glaucoma in USA (Ophthalmic)
- 21 Aug 2006 Icagen may selectively consider partnering opportunities for this programme(http://www.icagen.com)